Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The concentrations of C-reactive protein (CRP) and other acute-phase reactants that are increased by elevated serum levels of interleukin-6 correlate with disease activity. 11-17 Case series and a phase 2 trial have suggested that tocilizumab, an interleukin-6 receptor alpha inhibitor, allows for reductions in glucocorticoid doses that are used to control giant-cell arteritis and to maintain remission.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.